Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2009; 4(12): e8162.
Published online 2009 Dec 3. doi:  10.1371/journal.pone.0008162
PMCID: PMC2780295

Whole-Genome Gene Expression Profiling of Formalin-Fixed, Paraffin-Embedded Tissue Samples

Patrick Tan, Editor



We have developed a gene expression assay (Whole-Genome DASL®), capable of generating whole-genome gene expression profiles from degraded samples such as formalin-fixed, paraffin-embedded (FFPE) specimens.

Methodology/Principal Findings

We demonstrated a similar level of sensitivity in gene detection between matched fresh-frozen (FF) and FFPE samples, with the number and overlap of probes detected in the FFPE samples being approximately 88% and 95% of that in the corresponding FF samples, respectively; 74% of the differentially expressed probes overlapped between the FF and FFPE pairs. The WG-DASL assay is also able to detect 1.3–1.5 and 1.5–2 -fold changes in intact and FFPE samples, respectively. The dynamic range for the assay is ∼3 logs. Comparing the WG-DASL assay with an in vitro transcription-based labeling method yielded fold-change correlations of R2 ∼0.83, while fold-change comparisons with quantitative RT-PCR assays yielded R2∼0.86 and R2∼0.55 for intact and FFPE samples, respectively. Additionally, the WG-DASL assay yielded high self-correlations (R2>0.98) with low intact RNA inputs ranging from 1 ng to 100 ng; reproducible expression profiles were also obtained with 250 pg total RNA (R2∼0.92), with ∼71% of the probes detected in 100 ng total RNA also detected at the 250 pg level. When FFPE samples were assayed, 1 ng total RNA yielded self-correlations of R2∼0.80, while still maintaining a correlation of R2∼0.75 with standard FFPE inputs (200 ng).


Taken together, these results show that WG-DASL assay provides a reliable platform for genome-wide expression profiling in archived materials. It also possesses utility within clinical settings where only limited quantities of samples may be available (e.g. microdissected material) or when minimally invasive procedures are performed (e.g. biopsied specimens).


Formalin-fixed, paraffin-embedded (FFPE) tissues represent an invaluable resource for cancer research, as they are the most widely available material for which patient outcomes are known. There were over 300 million archived cancer tissue samples in the United States in 1999, with more samples accumulating at a rate of over 20 million per year [1]. The ability to perform gene expression profiling in these samples will enable both prospective and retrospective studies, and should greatly facilitate research in correlating expression profiles with clinical outcomes [2]. However, formalin fixation is known to render adenosine residues particularly prone to chemical modifications such as methylene dimerization and mono-methylolation [3] and generate degraded RNA fragments (up to 50% of which may not contain a poly-A tract) [4]. The degradation and chemical modification of RNA during tissue fixation and storage present challenges when applying conventional microarray technologies [3], [5][8].

To overcome the technical limitations to microarray-based analyses of FFPE samples, we previously developed a sensitive and reproducible gene expression profiling assay, DASL (cDNA-mediated annealing, selection, extension and ligation), for parallel analysis of hundreds of genes with highly degraded RNA samples [9][11]. The DASL assay incorporates random priming during cDNA synthesis, and therefore does not depend solely on poly-A/oligo-dT based priming. In addition, the assay requires a relatively short target sequence of about 50 nucleotides for query oligonucleotide annealing; thus, it can effectively quantify degraded RNA samples. While most other technologies rely on multiple rounds of random priming for sample amplification and labeling [3], DASL only generates first strand cDNA that minimizes variation that arises during the random priming. This technology has been successfully used to profile a variety of archived FFPE tumor samples, some of which have been in storage for as long as 24 years [12] and for which, in many cases, little or no tissue handling and fixation details are known, including colon [10], [11], breast [10], [11], [13][16], lung [11], [14], prostate [11], [12], [17][19], bladder [16], and liver [20] cancer. While all of these applications clearly demonstrated the utility of the technology for identification and validation of tissue and cancer-specific markers, the DASL assay was limited by the number of genes that could be profiled simultaneously (up to 1536 targets).

In this study, we extended the assay to include all 24K well-annotated RefSeq genes. We provide here a comprehensive characterization of the assay sensitivity and quantitative performance on FFPE tissues. This opens up new avenues for large-scale discovery, validation, and clinical applications of mRNA biomarkers in human diseases.


Assay Reproducibility

To assess the reproducibility of the WG-DASL assay we initially used inputs of 200 ng total RNA extracted from six different ovarian tumor FFPE tissues. The samples were labeled and hybridized as described in the Materials and Methods section. Each sample was assayed twice and the correlation was assessed for each FFPE tissue. Raw intensity scatterplots of a representative example, yielded a correlation coefficient R2 = 0.988 and a slope of approximately 45 degrees (Fig. 1A). When probe detection concordance rates (Detection p-value <0.01) were calculated between replicates, a high degree of overlap was obtained, with an average probe concordance rate of 94.6%. Detailed data for two representative FFPE samples are presented in Table 1.

Figure 1
WG-DASL assay reproducibility with variable RNA inputs.
Table 1
WG-DASL Assay Performance as a Function of FFPE RNA Input.

Profiling of two intact (100 ng) and artificially degraded (200 ng; 95°C for 30 min) cancer cell line RNAs (Raji and MCF-7) also yielded highly reproducible expression profiles, with an average correlation of R2∼0.989 (Fig. 1B, Table 2) and 0.985 (Fig. 1C, Table 2) for the intact and artificially degraded samples, respectively. Average probe concordance rates between replicates were 97.9% and 95.9% for the intact and artificially degraded samples, respectively (Table 2). Despite the relatively high degree of overlap of detected probes between the intact and the corresponding artificially degraded samples (∼93.9%), direct comparisons of the raw intensities between intact and artificially degraded samples yielded correlations of R2∼0.71. This is thought to be due to different degradation rates and/or secondary structures of mRNAs between intact and degraded samples [4], [21]. Therefore we performed fold-change comparisons in which intact sample pairs were compared to their corresponding degraded samples pairs. Using this approach highly correlated data were obtained, with an average R2 = 0.91 (Fig. 1D). This result suggests that our method can faithfully detect differentially expressed genes in intact as well as degraded samples.

Table 2
WG-DASL Assay Performance with Intact and Artificially Degraded RNA Inputs.

Comparison between Fresh-Frozen and FFPE Samples

We next assessed the performance of the WG-DASL assay in matched pairs of fresh frozen (FF) and FFPE samples, using RNAs derived from normal adjacent tissue (NAT) and tumor (TUM) lung tissue. We obtained a high degree of sensitivity, with the number of detected transcripts in both the NAT and TUM FFPE samples approximately 90% of that detected in the corresponding FF samples (Fig. 2A). Moreover, the overlap of the detected transcripts was also high, with 94.2% (14188/15064; NAT) and 96.3% (14066/14610; TUM) of the FFPE transcripts also detected in the corresponding FF sample (Fig. 2B). Direct intensity comparisons between matched FF and FFPE samples yielded average correlations of R2∼0.62; fold-change comparisons of several thousand detected transcripts between paired FF and FFPE samples were higher (average R2∼0.70, Fig. 2C), with a slope approximating 45 degrees and no significant compression or expansion observed for the log fold-change ratios. We also generated lists of differentially expressed transcripts between the TUM and NAT samples for both FF and FFPE tissues and then determined the extent of the overlap between the two differentially expressed transcript lists. With a false discovery rate (FDR) of <5%, approximately 74% (4793/6473) of the transcripts identified in the FFPE comparison also overlapped with those identified in the FF comparison (Fig. 2D). Similar overlapping results were obtained at a more stringent FDR (<1%) (Fig. S1).

Figure 2
Comparison between fresh-frozen (FF) and FFPE samples.

Fold-Change Detection and Dynamic Range

To further characterize the sensitivity of the WG-DASL assay, we designed an experiment to evaluate the ability of the assay to discriminate among different RNA mixtures. Total RNAs from Raji and MCF-7 cells were mixed in the following ratios: 100/0, 90/10, 75/25, 67/33, 50/50, 33/67, 25/75, 10/90 and 0/100% (corresponding to 1.0, 1.1, 1.3, 1.5, 2.0, 3.0, 4.0 and 10.0 fold-change respectively), with six replicates performed for each mixture and having a combined input of 100 ng in each case. Unsupervised hierarchical clustering revealed that the assay was able to accurately recapitulate the expected relationships among the different mixed samples (Fig. 3A).

Figure 3
Assay fold-change detection.

For a more rigorous analysis, we next selected a set of probes that were specific for the Raji cell line such that the detection p-value <0.01 for Raji, but >0.1 for MCF-7. Using these thresholds a set of 433 Raji-specific probes were obtained. The average signal intensities for this probe set in each mixture were calculated and then compared to that obtained for the 100% Raji RNA sample. With 98% of the Raji-specific probes detected in the 25–33% Raji/MCF-7 mixtures, the WG-DASL assay therefore is capable of detecting 1.3–1.5-fold changes in intact samples (Fig. 3B).

We next performed a similar experiment to assess the fold-change detection capabilities of the WG-DASL assay using FFPE samples. For this experiment RNAs from two different FFPE samples (DFCI #121 and DFCI #123) were mixed in the following ratios: 100/0, 75/25, 67/33, 50/50, 33/67, 25/75 and 0/100% (corresponding to 1.0, 1.3, 1.5, 2.0, 3.0 and 4.0 fold-change respectively), with six replicates performed for each mixture and having a combined input of 200 ng in each case. We then selected a set of probes that were specific for the DFCI #121 sample such that the detection p-value <0.01 for DFCI #121, but >0.01 for DFCI #123. Using these thresholds a set of 154 DFCI #121-specific probes were obtained. The average signal intensities for this probe set in each mixture were calculated and then compared to that obtained for the 100% DFCI #121 sample. With 82–98% of the DFCI #121-specific probes detected in the 33–50% DFCI #121/123 mixtures, the WG-DASL assay therefore is capable of detecting 1.5–2-fold changes in FFPE samples (Fig. 3C).

The WG-DASL assay also yielded a dynamic range of ∼3 logs as determined by serial dilutions of artificially synthesized RNAs spiked into a background of 100 ng total Raji RNA (Fig. S2).

Performance with Low Inputs

Having obtained robust expression profiling data with 100 ng intact total RNA, we next sought to determine the performance of the WG-DASL assay at lower RNA input levels. For this purpose various amounts (100 ng, 50 ng, 10 ng, 5 ng, 1 ng, 250 pg, 100 pg and 10 pg) of Raji and MCF-7 total RNAs were assayed. For both cell lines, data generated with as little as 250 pg still yielded reproducible expression profiles with an average correlation of R2∼0.92 (Fig. 4A, Table 3), while the 50 pg and 10 pg RNA inputs yielded average intensity correlations of R2∼0.82 and 0.78, respectively (Table 3). On average, the probe overlap as compared to 100 ng was 71.7%, 42.6% and 22.9% for the 250, 50 and 10 pg inputs respectively (Table 3). Comparison of expression profiles generated with the lower inputs to that obtained with the standard 100 ng input revealed average intensity correlations of R2∼0.91 for the 250 pg (Fig. 4B), and R2∼0.80 and 0.72 for the 50 pg and 10 pg inputs, respectively (Table 3). To further assess the ability of the WG-DASL assay to detect differentially expressed genes with lower inputs we compared lists of differentially expressed transcripts detected at the 250 pg level to that obtained with the standard 100 ng input. Using a p-value  = 0.001 cutoff, approximately 95.5% (10716/11222 probes) of the differentially expressed transcripts in the 250 pg input was also identified in the standard 100 ng input (Fig. 4C).

Figure 4
WG-DASL assay performance with low RNA inputs.
Table 3
WG-DASL Assay Performance as a Function of Intact RNA Input.

To assess the performance of the WG-DASL assay with limiting quantities of FFPE samples, we performed a similar experiment as described for the intact samples, using two FFPE samples (DFCI #120 and DFCI #129) with total RNA inputs as follows: 200 ng, 50 ng, 10 ng, 5 ng, 1 ng and 250 pg. Each sample was assayed twice. For both FFPE samples, inputs as low as 5 ng yielded detected probe concordance (overlap) rates of >85% and raw intensity correlations of R2>0.85 when compared with standard inputs of 200 ng (Table 1). Moreover, these results were reproducible with self-correlations of R2>0.90. Despite the lower probe concordance rates (∼60%) between the 1 ng input and the standard 200 ng input, the raw expression profiles at the 1 ng input level remained reproducible, with R2∼0.80 and had correlations of R2>0.75 when compared with the standard 200 ng input.

Comparison and Validation of the WG-DASL Assay with IVT-Based Microarray Profiling and Real-Time Quantitative PCR Methods

To validate the global expression profiles obtained with the WG-DASL assay, 100 ng total RNA derived from MCF-7 and Raji cells were labeled using an in vitro transcription (IVT)-based method [22] and hybridized to the same microarray. The IVT-method employed here allows linearly amplified cRNA to be directly hybridized to the same type of whole genome expression BeadChip as that used in the WG-DASL assay and provides an independent means by which different labeling methods may be compared on a global scale. Fold-change (i.e. Raji/MCF-7) data derived from both the WG-DASL assay and the IVT-method were then extracted and compared. Our analysis yielded reproducible and highly similar results, with an average correlation of R2∼0.80 (Fig. 5A), indicative of a high degree of measurement concordance between the two different gene expression platforms.

Figure 5
Validation with in vitro transcription-based and qRT-PCR assays.

We also compared the WG-DASL assay results to that obtained with real-time quantitative PCR (qRT-PCR). For comparisons in intact RNAs we designed a set of primers corresponding to a panel of 24 genes, whose expression levels differed between the assayed cell lines (Raji and MCF-7). Using the “fold-change” method described earlier, our comparisons across these 24 common genes between the WG-DASL (100 ng input RNA) and the qRT-PCR assays consistently demonstrated, on average, a strong correlation (R2∼0.87) across replicate experiments (Fig. 5B). Furthermore, a similar degree of concordance (R2∼0.85) was maintained even when the WG-DASL assay was performed with 250 pg RNA input (Fig. 5C). We noted a compression of the WG-DASL fold-change data as compared to that obtained with the qRT-PCR assay – a phenomenon that has been previously reported for microarray-based expression analysis [9], [23]. For comparisons in FFPE-derived RNAs we designed a set of primers corresponding to a panel of 12 genes, with amplicon sizes ranging from 70–85 bp. We then compared WG-DASL and qRT-PCR data (Table S1) obtained for three ovarian cancer FFPE samples (DFCI #79, 98 and 118). Across the 12 assayed genes we obtained fold-change correlations of R2 = 0.63 for DFCI #79/98, R2 = 0.61 for DFCI #98/118 and R2 = 0.42 for DFCI #79/118, yielding an average of R2 = 0.55 for all three paired combinations.


Over the last two decades, significant strides have been made in RNA profiling in FFPE tissues, including efforts to standardize tissue handling and fixation procedures [24], [25] and improving RNA extraction methodologies for FFPE tissues [13], [26], [27]. Despite these advancements, very few technologies have emerged that are capable of robust whole transcriptome profiling in archived FFPE materials. Initial attempts at large-scale expression profiling in FFPE tissues yielded either poor reproducibility and sensitivity [28] or loss of gene signature information when compared with matched FF samples [29]. Most recently, several commercial and academic endeavors have focused on improving the efficiency of amplification and labeling of FFPE-derived RNAs and have met with varying degrees of success [5][8], [30][34]. While in some instances these technologies have demonstrated their ability to retrieve meaningful biological information from degraded samples [27], [35], concerns remain centered largely around the capability with which older archived tissues (>10 years) can be routinely profiled [29], [31] as well as reports of low signal intensities and poor (transcript) detection sensitivity in FFPE tissues [5], [7], [36].

Here we describe the development of a robust and highly sensitive profiling assay capable of generating high quality expression profiles in degraded/FFPE samples at a whole-transcriptome level. The assay is highly reproducible with as little as 50 ng total RNA extracted from FFPE tissues (R2>0.97). It is capable of accurately detecting 1.3–1.5 and 1.5–2 fold changes in intact and FFPE samples, respectively, with a dynamic range of 3 logs. Comparisons between matched FF and FFPE tissues yielded a high degree of profile concordance with a large number of transcripts robustly detected in both FF and FFPE samples. Detailed comparisons between normal and tumor FF and FFPE sample sets yielded significant fold-change correlations of R2∼0.70 and >70% of the differentially expressed transcripts shared between both FF and FFPE sample sets. For qRT-PCR vs. WG-DASL comparisons we, like others [5], also noted poorer correlations for genes with low array signal intensities, which adversely impacted the overall platform concordance. Despite this effect we obtained an average fold-change correlation of R2 = 0.55, a result which is consistent with that reported for other studies [5], [36]. Given its overall performance at this level, the WG-DASL assay now enables studies that previously would have been difficult, for example, using archival tissue blocks for either retrospective or prospective randomized trials. Indeed, it has already been successfully applied to interrogate global gene expression patterns in stage I serous invasive versus borderline ovarian tumors [37].

In addition to enabling whole-genome RNA profiling in FFPE tissues, the WG-DASL assay also performs well with low RNA inputs. With as little as 250 pg of intact total RNA (∼25 cell equivalent), the assay still maintains good reproducibility (R2 = 0.92) without significantly compromising either the intensity correlation (R2 = 0.91), sensitivity (>70%) or differential transcript overlap (>85%) when compared with standard amounts of RNA input (100 ng). For FFPE-derived RNAs, inputs as low as 1 ng total RNA generated reproducible expression profiles with R2∼0.80, while still maintaining a correlation of R2∼0.75 when compared with standard FFPE inputs (200 ng). Therefore, this technology is particularly useful for clinical research where minimally invasive procedures often yield limiting amounts of starting material such as fine needle biopsies and circulating tumor cells.

Materials and Methods

RNA Samples

Cancer cell line RNAs, breast adenocarcinoma (MCF-7) and Burkitts Lymphoma (Raji), were purchased from Applied Biosystems Inc/Ambion (Austin, TX, USA). For comparisons between fresh frozen and FFPE tissues we used matched lung tissue samples from a tumor and the normal adjacent tissue that were preserved as fresh-frozen and FFPE tissue. RNA was extracted from the fresh frozen tissue using a standard RNeasy protocol (QIAGEN GmbH, Hilden, Germany), while FFPE RNAs were isolated from 10 µm sections using the FormaPure Kit (Agencourt Bioscience Corporation, Beverly, MA, USA). The archival age for the lung FFPE tissues was 3 years. RNAs from ovarian tumor FFPE samples, with archival ages ranging from 8–13 years, were extracted using the RNeasy FFPE Kit (QIAGEN GmbH, Hilden, Germany) according to the manufacturer's instructions with a few modifications described next. Punch biopsies (3–4), 0.6 mm in diameter, were obtained from each tissue block and were placed in a tube containing 1 ml xylene. Immediately after the 100% ethanol extraction step, an additional 70% ethanol extraction was performed. Proteinase K digestions were at 55°C for 35 min followed by 80°C for 25 min. Genomic DNA was removed by centrifugation in gDNA Eliminator spin columns at 8000 x g for 1 min, after which a volume of 1400 µl ethanol was added to the flow-through fraction, resulting in three passes through the RNeasy MinElute spin column. The first Buffer RPE wash was performed at 8000 x g for 1 min and prior to the final elution the dried spin column membranes were incubated in 30 µl RNase-free water for 10 min at room temperature before centrifugation.

Whole Genome DASL Assay Workflow

The Whole-Genome DASL assay is derived from a previously described high throughput gene expression system, the cDNA-mediated annealing, selection, extension and ligation (DASL) assay [9], but differs from the original assay by having improved multiplexing capability, thereby significantly increasing the number of transcripts that may be assayed in parallel, while still retaining the ability to profile degraded samples. Briefly, total RNA was converted to cDNA using biotinylated oligo-dT18 and random nonamer primers. Two assay-specific oligonucleotides were designed to interrogate a single contiguous 50 nt sequence on each cDNA. Each of these oligonucleotides consisted of two parts: an upstream-specific oligonucleotide (USO) containing a 3′ gene-specific sequence and a 5′ universal PCR primer sequence (P1), while the downstream-specific oligonucleotide (DSO) contained a 5′ gene-specific sequence and a different 3′ universal PCR primer sequence (P2′). The USOs and DSOs were designed with an average Tm of 65°C and 58°C, respectively and an average length of 22 and 20 nt, respectively. Using this approach, a total of 24526 oligonucleotide pairs (probes) were designed and pooled, which together constituted the whole genome DASL assay pool (DAP), corresponding to 18626 unique genes, based on well-annotated content derived from the National Center for Biotechnology Information Reference Sequence Database (Build 36.2, Release 22)). The DAP was then annealed to the targeted cDNAs during a 16 h temperature gradient (70 to 30°C) incubation followed by enzymatic extension and ligation steps, as previously described [9]. Ligated products were PCR-amplified and labeled with a universal Cy3-coupled primer after which single-stranded labeled products were precipitated and then hybridized to whole genome gene expression BeadChips as previously described [22]. BeadChips were then scanned on a BeadArray™ Reader using BeadScan software (v3.2), during which fluorescence intensities were read and images extracted. Scanned data were then uploaded into GenomeStudio® software (v1.1), via the gene expression module (WG-DASL Assay) for further analysis. All of the microarray data are MIAME compliant and have been submitted to GEO (Accession Number: GSE17599).

Microarray Data Analysis

Unless otherwise stated, all data were analyzed in an un-normalized, raw state. All individual samples were assayed a minimum of two times and in certain instances as many as six replicates were performed. Data quality was assessed using several assay controls and Detection p-values were computed using several hundred negative controls to determine gene expression detection limits. Unsupervised hierarchical clustering was performed in GenomeStudio using Pearson's correlation coefficient and average linkage clustering. Assay performance metrics are described further in the Results section.

Real-Time Quantitative RT-PCR (qRT-PCR)

Total RNAs were converted to cDNA using the WG-DASL assay workflow described earlier. For quantifying intact RNAs, a set of 24 primers was used to amplify approximately 200 bp fragments, while for FFPE-derived RNAs a set of 12 primers was designed to generate 70–85 bp amplicons. qRT-PCR analyses were performed on the ABI Prism 7900HT sequence detection system (Applied Biosystems Inc, Foster City, CA, USA) as described previously [9]. In brief, reactions contained 1 µl cDNA template (the equivalent of 1 ng intact RNA or 2 ng FFPE-derived RNA obtained from a serial dilution of the original WG-DASL assay-derived cDNA), 0.25 µM each of forward and reverse primer (Invitrogen, Carlsbad, CA, USA) and 5 µl SYBR Green PCR Master Mix (Applied Biosystems Inc, Foster City, CA, USA) in a total volume of 10 µl. PCR amplifications consisted of an initial enzyme activation step at 95°C for 12 min followed by 40 cycles of 95°C for 20 sec, 54°C for 20 sec and 72°C for 30 sec.

Supporting Information

Figure S1

Differential gene expression overlap between FF and FFPE samples at FDR <1%. Lists of differentially expressed probes were generated by comparing replicates of the NAT and TUM tissues with a false discovery rate (FDR) cutoff of <1%. The overlap of differentially expressed probes between the FF and FFPE matched samples for both the NAT and TUM tissues was calculated as the percentage of differentially expressed FFPE probes also detected in the corresponding FF sample.

(6.76 MB TIF)

Figure S2

WG-DASL assay dynamic range. Intensity data from eight synthetic RNAs are shown as the number of input RNA molecules (x-axis) vs. log10 intensity (y-axis). Experiments were performed in duplicate and the error bars were calculated as the standard error of the mean.

(6.76 MB TIF)

Table S1

qRT-PCR and WG-DASL Assay Data for FFPE Tissues.

(0.07 MB DOC)


We would like to thank Marina Bibikova, Mark Staebell and Brent Applegate at Illumina, Monica Reinholz and Robert Jenkins at Mayo Clinic for helpful discussions.


Competing Interests: CA, BK, TR, TB, JI, and JBF are employees of Illumina, Inc. DC and WJ are employees of Expression Analysis, Inc. The study used the whole-genome DASL product developed at Illumina.

Funding: This work was supported in part by grants from the Madeline Franchi Ovarian Cancer Research Fund, the Claudia Adams Barr Program, and a grant from the US National Cancer Institute (P50 CA105009). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


1. Bouchie A. Coming soon: a global grid for cancer research. Nat Biotechnol. 2004;22:1071–1073. [PubMed]
2. Ramaswamy S. Translating cancer genomics into clinical oncology. N Engl J Med. 2004;350:1814–1816. [PubMed]
3. Farragher SM, Tanney A, Kennedy RD, Paul Harkin D. RNA expression analysis from formalin fixed paraffin embedded tissues. Histochem Cell Biol. 2008;130:435–445. [PubMed]
4. Masuda N, Ohnishi T, Kawamoto S, Monden M, Okubo K. Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples. Nucleic Acids Res. 1999;27:4436–4443. [PMC free article] [PubMed]
5. Linton KM, Hey Y, Saunders E, Jeziorska M, Denton J, et al. Acquisition of biologically relevant gene expression data by Affymetrix microarray analysis of archival formalin-fixed paraffin-embedded tumours. Br J Cancer. 2008;98:1403–1414. [PMC free article] [PubMed]
6. Coudry RA, Meireles SI, Stoyanova R, Cooper HS, Carpino A, et al. Successful application of microarray technology to microdissected formalin-fixed, paraffin-embedded tissue. J Mol Diagn. 2007;9:70–79. [PMC free article] [PubMed]
7. Scicchitano MS, Dalmas DA, Bertiaux MA, Anderson SM, Turner LR, et al. Preliminary comparison of quantity, quality, and microarray performance of RNA extracted from formalin-fixed, paraffin-embedded, and unfixed frozen tissue samples. J Histochem Cytochem. 2006;54:1229–1237. [PubMed]
8. Tomlins SA, Mehra R, Rhodes DR, Shah RB, Rubin MA, et al. Whole transcriptome amplification for gene expression profiling and development of molecular archives. Neoplasia. 2006;8:153–162. [PMC free article] [PubMed]
9. Fan JB, Yeakley JM, Bibikova M, Chudin E, Wickham E, et al. A versatile assay for high-throughput gene expression profiling on universal array matrices. Genome Res. 2004;14:878–885. [PMC free article] [PubMed]
10. Bibikova M, Talantov D, Chudin E, Yeakley JM, Chen J, et al. Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays. Am J Pathol. 2004;165:1799–1807. [PMC free article] [PubMed]
11. Bibikova M, Yeakley JM, Chudin E, Chen J, Wickham E, et al. Gene expression profiles in formalin-fixed, paraffin-embedded tissues obtained with a novel assay for microarray analysis. Clin Chem. 2004;50:2384–2386. [PubMed]
12. Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst. 2008;100:815–825. [PMC free article] [PubMed]
13. Abramovitz M, Ordanic-Kodani M, Wang Y, Li Z, Catzavelos C, et al. Optimization of RNA extraction from FFPE tissues for expression profiling in the DASL assay. Biotechniques. 2008;44:417–423. [PMC free article] [PubMed]
14. Haller AC, Kanakapalli D, Walter R, Alhasan S, Eliason JF, et al. Transcriptional profiling of degraded RNA in cryopreserved and fixed tissue samples obtained at autopsy. BMC Clin Pathol. 2006;6:9. [PMC free article] [PubMed]
15. Paik S. Methods for gene expression profiling in clinical trials of adjuvant breast cancer therapy. Clin Cancer Res. 2006;12:1019s–1023s. [PubMed]
16. Ravo M, Mutarelli M, Ferraro L, Grober OM, Paris O, et al. Quantitative expression profiling of highly degraded RNA from formalin-fixed, paraffin-embedded breast tumor biopsies by oligonucleotide microarrays. Lab Invest. 2008;88:430–440. [PubMed]
17. Bibikova M, Chudin E, Arsanjani A, Zhou L, Garcia EW, et al. Expression signatures that correlated with Gleason score and relapse in prostate cancer. Genomics. 2007;89:666–672. [PubMed]
18. Li HR, Wang-Rodriguez J, Nair TM, Yeakley JM, Kwon YS, et al. Two-dimensional transcriptome profiling: identification of messenger RNA isoform signatures in prostate cancer from archived paraffin-embedded cancer specimens. Cancer Res. 2006;66:4079–4088. [PubMed]
19. Nakagawa T, Kollmeyer TM, Morlan BW, Anderson SK, Bergstralh EJ, et al. A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS ONE. 2008;3:e2318. [PMC free article] [PubMed]
20. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008;359:1995–2004. [PMC free article] [PubMed]
21. Lee J, Hever A, Willhite D, Zlotnik A, Hevezi P. Effects of RNA degradation on gene expression analysis of human postmortem tissues. Faseb J. 2005;19:1356–1358. [PubMed]
22. Kuhn K, Baker SC, Chudin E, Lieu MH, Oeser S, et al. A novel, high-performance random array platform for quantitative gene expression profiling. Genome Res. 2004;14:2347–2356. [PMC free article] [PubMed]
23. Yuen T, Wurmbach E, Pfeffer RL, Ebersole BJ, Sealfon SC. Accuracy and calibration of commercial oligonucleotide and custom cDNA microarrays. Nucleic Acids Res. 2002;30:e48. [PMC free article] [PubMed]
24. Medeiros F, Rigl CT, Anderson GG, Becker SH, Halling KC. Tissue handling for genome-wide expression analysis: a review of the issues, evidence, and opportunities. Arch Pathol Lab Med. 2007;131:1805–1816. [PubMed]
25. Hewitt SM, Lewis FA, Cao Y, Conrad RC, Cronin M, et al. Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med. 2008;132:1929–1935. [PubMed]
26. Ribeiro-Silva A, Zhang H, Jeffrey SS. RNA extraction from ten year old formalin-fixed paraffin-embedded breast cancer samples: a comparison of column purification and magnetic bead-based technologies. BMC Mol Biol. 2007;8:118. [PMC free article] [PubMed]
27. Linton K, Hey Y, Dibben S, Miller C, Freemont A, et al. Methods comparison for high-resolution transcriptional analysis of archival material on Affymetrix Plus 2.0 and Exon 1.0 microarrays. Biotechniques. 2009;47:587–596. [PubMed]
28. Karsten SL, Van Deerlin VM, Sabatti C, Gill LH, Geschwind DH. An evaluation of tyramide signal amplification and archived fixed and frozen tissue in microarray gene expression analysis. Nucleic Acids Res. 2002;30:E4. [PMC free article] [PubMed]
29. Penland SK, Keku TO, Torrice C, He X, Krishnamurthy J, et al. RNA expression analysis of formalin-fixed paraffin-embedded tumors. Lab Invest. 2007;87:383–391. [PubMed]
30. Chung CH, Parker JS, Ely K, Carter J, Yi Y, et al. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res. 2006;66:8210–8218. [PubMed]
31. Paik S, Kim CY, Song YK, Kim WS. Technology insight: Application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer. Nat Clin Pract Oncol. 2005;2:246–254. [PubMed]
32. Hosey AM, Gorski JJ, Murray MM, Quinn JE, Chung WY, et al. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst. 2007;99:1683–1694. [PubMed]
33. Knight JF, Shepherd CJ, Rizzo S, Brewer D, Jhavar S, et al. TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer. Br J Cancer. 2008;99:1849–1858. [PMC free article] [PubMed]
34. Fedorowicz G, Guerrero S, Wu TD, Modrusan Z. Microarray analysis of RNA extracted from formalin-fixed, paraffin-embedded and matched fresh-frozen ovarian adenocarcinomas. BMC Med Genomics. 2009;2:23. [PMC free article] [PubMed]
35. Casey T, Bond J, Tighe S, Hunter T, Lintault L, et al. Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer. Breast Cancer Res Treat. 2009;114:47–62. [PubMed]
36. Lassmann S, Kreutz C, Schoepflin A, Hopt U, Timmer J, et al. A novel approach for reliable microarray analysis of microdissected tumor cells from formalin-fixed and paraffin-embedded colorectal cancer resection specimens. J Mol Med. 2009;87:211–224. [PubMed]
37. Chien J, Fan JB, Bell DA, April C, Klotzle B, et al. Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer. Gynecol Oncol. 2009;114:3–11. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science
PubReader format: click here to try


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • BioProject
    BioProject links
  • Compound
    PubChem chemical compound records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records. Multiple substance records may contribute to the PubChem compound record.
  • GEO DataSets
    GEO DataSets
    Gene expression and molecular abundance data reported in the current articles that are also included in the curated Gene Expression Omnibus (GEO) DataSets.
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...